RXST SHAREHOLDERS: RxSight, Inc. Stock Drop Triggers Securities Fraud Class Action – Contact BFA Law by September 22 if You Lost Money (NASDAQ:RXST)

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., et al., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, led to another 38% decline in stock price, dropping from $12.79 to $7.95 per share [6].